Effecten van granaatappelsap op colitis ulcerosa
Effect van granaatappelsap op darmontsteking, kwaliteit van leven en het darmmicrobioom bij patiënten met colitis ulcerosa: een pilotstudie
The purpose of this study is to determine whether consumption of 237 ml of pomegranate juice daily for 8 weeks will:
- lower inflammation (in the gut as well as generally in the body) and improve your overall quality of life
- affect the microbes living in the gut (gut microbiota)
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
the study is aimed at evaluating the effects of pomegranate juice (PomJ) on: 1) gut inflammation (fecal calprotectin and Simple Clinical Colitis Activity Index) and quality of life; 2) circulating inflammatory markers (e.g., hs-CRP, IL-6, IL-10, TNF-a, IL-1b, IL-8, LBP, LPS) and markers of oxidative stress (blood and urine malondialdehyde (MDA)) and 3) gut microbiota composition and functionality (urinary and circulating urolithin metabolites, fecal SCFAs/BAs, blood LBP and LPS, etc.). We will perform a randomized, controlled, 16-week trial to generate preliminary evidence on the effects of PomJ consumption in patients with mild-to-moderate UC. Participants will be randomly assigned to one of two groups: intervention group and delayed start group. The study will involve 2 phases, each lasting for 8 weeks. During Phase 1, the intervention group will consume 237 ml of PomJ daily, while the delayed start group will follow their habitual diet. Data generated from the delayed start group during Phase 1 will serve as the control for the study. During Phase 2, the intervention group will stop consuming PomJ and switch to consuming their habitual diet, while the delayed start group will consume 237 ml of PomJ daily for 8 weeks. Data generated from the intervention group during Phase 2 will serve as a follow-up to explore whether the effects of PomJ consumption persist after consumption is stopped (this will be an exploratory outcome).
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Tatiana Diacova, PhD, MS, RDN
- Telefoonnummer: 310-206-8292
- E-mail: tdiacova@mednet.ucla.edu
Studie Locaties
-
-
California
-
Los Angeles, California, Verenigde Staten, 90073
- Nog niet aan het werven
- West Los Angeles VA Medical Center
-
Hoofdonderzoeker:
- Zhaoping Li, MD, PhD
-
Contact:
- Tatiana Diacova, PhD, MS, RD
- Telefoonnummer: 310-206-8292
- E-mail: tdiacova@mednet.ucla.edu
-
Los Angeles, California, Verenigde Staten, 90095
- Werving
- UCLA Center for Human Nutrition
-
Hoofdonderzoeker:
- Zhaoping Li, MD, PhD
-
Contact:
- Tatiana Diacova, PhD, MS, RD
- Telefoonnummer: 310-206-8292
- E-mail: tdiacova@mednet.ucla.edu
-
Onderonderzoeker:
- Berkeley Limketkai, MD, PhD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
• Adults ≥ 18 yo
- Following a low-polyphenol and fiber diet (< 3 servings of fruits/vegetables per day)
- Mild-to-moderate UC at the time of screening (2 ≤ partial Mayo scores ≤ 5)
- Supportive evidence of active inflammation (hsCRP >1 mg/L, fecal calprotectin >50 µg/g stool, or abnormal lower endoscopy) in individuals with biopsy-proven UC
- Patients on 5-aminosalicylates must be on a stable dose for ≥ 4 weeks prior to screening
- Patients on treatment with immunosuppressive therapy (e.g., azathioprine/6-mercaptopurine, methotrexate) must be on stable dose for 8 weeks prior to baseline visit
- At the time of baseline visit, patients may be on no more than 20 mg/day of prednisone and 9 mg/day of budesonide MMX
- Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent.
Exclusion Criteria:
-
• Non-English speaker
- Vegetarian/vegan
- Known pomegranate allergy
- Documented chronic disease besides UC, including diabetes, renal or liver diseases, metabolic syndrome, active cancer, MI or stroke, history of gastric bypass
- Patients with CD, indeterminate/severe to fulminant colitis
- History of colectomy or colonic dysplasia
- Presence of ileal pouch or ostomy
- Evidence of active bacterial or viral gastroenteritis as indicated by positive stool studies for ova & parasites, Clostridium difficile, and stool culture
- Recent hospitalizations (within 2 weeks of screening) for UC requiring IV steroids
- Presence of the following labs indicative of severe colitis: a. Hemoglobin < 8.0 g/dl b. Albumin < 3.0 g/dl
- Recent systemic antibiotics use (within 3 months of screening) or active use of anti-diarrheal medications
- Taking supplements known to affect metabolism or gut microbiota composition (probiotics, fiber, etc.), unless willing to stop for the study duration
- Use of Total Parenteral Nutrition (TPN)
- Use of cyclosporine, tacrolimus, or thalidomide within 2 months prior to screening
- Taking exogenous hormones (e.g., hormone replacement therapy)
- Recent weight fluctuations (>10% in the last 6 months)
- Smoker or living with a smoker
- Use of >20 g of alcohol per day
- Unable or unwilling to comply with the study protocol (including unwillingness to avoid watermelon and other lycopene-rich foods for the whole duration of the study)
- Unable to provide consent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Intervention
Participants in this arm will be consuming 237 ml of pomegranate juice for the first 8 weeks of the study and their habitual diet without pomegranate juice for the second 8 weeks |
237 ml of pomegranate juice for the first 8 weeks -> habitual diet for the second 8 weeks |
|
Experimenteel: Delayed start
Participants in this arm will consume their habitual diet for the first 8 weeks of the study and drink 237 ml of pomegranate juice for the second 8 weeks |
habitual diet for the first 8 weeks -> 237 ml of pomegranate juice for the second 8 weeks |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
simple clinical colitis activity index (SCCAI)
Tijdsspanne: At baseline, 8 weeks and 16 weeks
|
Simple Clinical Colitis Activity Index (SCCAI) includes questions about bowel frequency, urgency of defecation, etc. Measured by the number of points/scores. |
At baseline, 8 weeks and 16 weeks
|
|
Fecal calprotectin
Tijdsspanne: At baseline, 8 weeks and 16 weeks
|
To evaluate effects of PomJ on gut inflammation in patients with mild-to-moderate UC. The primary outcome will be levels of fecal calprotectin (objective measure). Fecal calprotectin levels will be assessed via a commercially available ELISA kit in mcg/g. |
At baseline, 8 weeks and 16 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Biomarkers of inflammation and oxidative stress
Tijdsspanne: At baseline, week 8 and week 16
|
Blood interleukin-6 (IL-6) in pg/ml |
At baseline, week 8 and week 16
|
|
Biomarkers of inflammation and oxidative stress
Tijdsspanne: At baseline, week 8 and week 16
|
Blood interleukin-10 (IL-10) in pg/ml |
At baseline, week 8 and week 16
|
|
Biomarkers of aging and oxidative stress
Tijdsspanne: At baseline, week 8 and week 16
|
Blood TNF-a in pg/ml |
At baseline, week 8 and week 16
|
|
Biomarkers of inflammation and oxidative stress
Tijdsspanne: At baseline, week 8 and 16
|
Blood IL-1b in pg/ml |
At baseline, week 8 and 16
|
|
Biomarkers of inflammation and oxidative stress
Tijdsspanne: At baseline, weeks 8 and 16
|
Blood IL-8 in pg/ml |
At baseline, weeks 8 and 16
|
|
Biomarkers of inflammation and oxidative stress
Tijdsspanne: At Baseline, weeks 8 and 16
|
Blood hs-CRP in mg/ml |
At Baseline, weeks 8 and 16
|
|
Biomarkers of inflammation and oxidative stress
Tijdsspanne: At baseline, weeks 8 and 16
|
Urine malondialdehyde (MDA) in ng/ml |
At baseline, weeks 8 and 16
|
|
Biomarkers of inflammation and oxidative stress
Tijdsspanne: At baseline, weeks 8 and 16
|
Blood MDA in nmol/ml |
At baseline, weeks 8 and 16
|
|
Biomarkers of inflammation and oxidative stress
Tijdsspanne: At baseline, weeks 8 and 16
|
Urine 8OHdG in ng/mg |
At baseline, weeks 8 and 16
|
|
Biomarkers of inflammation and oxidative stress
Tijdsspanne: At baseline, weeks 8 and 16
|
Blood 8OHdG in ng/ml |
At baseline, weeks 8 and 16
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Gut-derived metabolites
Tijdsspanne: At baseline, weeks 8 and 16
|
Blood urolithin metabolites in micromoles/L |
At baseline, weeks 8 and 16
|
|
Gut-derived metabolites
Tijdsspanne: At baseline, weeks 8 and 16
|
Urine urolithin metabolites |
At baseline, weeks 8 and 16
|
|
Microbial inflammatory components
Tijdsspanne: At baseline, weeks 8 and 16
|
Blood lipopolysaccharide in ng/ml |
At baseline, weeks 8 and 16
|
|
Microbial inflammatory components
Tijdsspanne: At baseline, weeks 8 and 16
|
Blood LPS binding protein in micrograms/ml |
At baseline, weeks 8 and 16
|
|
Microbial-derived metabolites
Tijdsspanne: At baseline, weeks 8 and 16
|
Fecal short-chain fatty acids (SCFAs) in micromoles/g |
At baseline, weeks 8 and 16
|
|
Microbial-derived metabolites
Tijdsspanne: At baseline, weeks 8 and 16
|
Fecal bile acids (BAs) in ng/ml |
At baseline, weeks 8 and 16
|
|
Gut microbiota composition
Tijdsspanne: At baseline, weeks 8 and 16
|
The stool specimen will be collected by the participants at home at baseline and week 12 utilizing our Stool Collection Kit as per instructions. Immediately after collection, the specimen will be frozen in a home freezer and delivered in an insulated container to the UCLA Center for Human Nutrition. At UCLA, the specimen will be stored at - 80 ºC. Fecal microbiological analyses. Approximately 1g of the stool will be weighed and dried in a vacuum drying oven (15 in Hg) at 80 ºC for 48 hours, then weighed again to establish the moisture content so that all counts can be corrected to dry weight. From another aliquot of remaining fecal samples, DNA will be extracted using bead beating with a commercial extraction system (DNeasy PowerSoil® DNA Isolation Kit, Qiagen, Valencia, CA). The quality of the DNA samples will be confirmed using a Nanodrop 1000 (Thermo Fisher Scientific, Wilmington, DE). Extracted DNA will be transferred to UCLA Microbiome Core facility for MiSeq sequencing. |
At baseline, weeks 8 and 16
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Zhaoping Li, MD, PhD, University of California, Los Angeles
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- IRB-25-1553
- T32DK007180 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Data analysis will be performed in-house.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .